Lipocine (LPCN) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Lipocine Analyst Ratings
BenzingaSep 24 10:26 ET · Ratings
A. G. P. Initiates Lipocine(LPCN.US) With Buy Rating, Announces Target Price $10
Moomoo NewsSep 24 08:32 ET · Ratings
Express News | Lipocine Inc : Alliance Global Partners Initiates Coverage With Buy Rating; Target Price $10
ReutersSep 24 08:09 ET
Express News | Lipocine Announces Phase 2 Data on Lpcn 2401 to Be Presented at Obesityweek®
ReutersSep 5 08:00 ET
Lipocine Announces Phase 2 Data on LPCN 2401 to Be Presented at ObesityWeek
PR NewswireSep 5 08:00 ET
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference
PR NewswireAug 27 08:00 ET

Comments

Jaguar8

Sep 5 07:02

NEES

$Lipocine (LPCN.US)$
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
Study evaluated LPCN 2401 in participants with obesity (BMI ≥30) and participants with BMI ≥27 with at least one weight-related comorbidity
SALT LAKE CITY, Sept. 5, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that a poster featuring Phase 2 da...

3

Meltyy

Jul 17 22:40

Smid-cap obesity stocks hit by $RHHBY positive Ph1 data for oral GLP-1 obesity drug ⚠️

$ROCHE HOLDING AG (RHHBY.US)$
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co (LLY.US)$ $Novo-Nordisk A/S (NVO.US)$ $Structure Therapeutics (GPCR.US)$ $Viking Therapeutics (VKTX.US)$ $Lipocine (LPCN.US)$

6

Meltyy

May 12 21:23

🎯 Ph 3 readouts in Q2 2024...

$United Therapeutics (UTHR.US)$ Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Liquidia (LQDA.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$MorphoSys (MOR.US)$ Phase 3
$Immunocore (IMCR.US)$ Phase 3
$Crinetics (CRNX.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$Capricor Therapeutics (CAPR.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3...

14

1

Jaguar8

May 8 07:03

$Lipocine (LPCN.US)$
NEWS
LIPOCINE ANNOUNCES LATE BREAKING ORAL PRESENTATION OF DATA FROM THE PHASE 2 STUDY OF LPCN 1148 AT EASL CONGRESS 2024
Lipocine Inc. announced that data from the Phase 2 study of LPCN 1148 will be presented at the EASL Congress 2024 in Italy. The study shows improvement in sarcopenia and hepatic encephalopathy in cirrhosis patients.
Positive
Data from the Phase 2 study of LPCN 1148 selected for late breaking oral presentation at EASL Congress 2024.
Intervention with oral L...

Trytosaveabit

May 1 07:01

Watching for data release

$Lipocine (LPCN.US)$ Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, Lpcn 1154. Lipocine Inc: Topline Results Anticipated Late in 2Q 2024

1

LPCN Lipocine

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target